The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma
Open accessAbstract
Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in 50% (22 of 44) of resistant BCCs and show that these mutations maintain Hedgehog signaling in the presence of SMO inhibitors. Alterations include four ligand binding pocket mutations defining sites of inhibitor binding and four variants conferring constitutive activity and inhibitor resistance, illuminating pivotal residues that ensure receptor autoinhibition. In the presence of a SMO inhibitor, tumor cells containing either class of SMO mutants effectively outcompete cells containing the wild-type SMO. Finally, we show that both classes of SMO variants respond to aPKC-ι/λ or GLI2 inhibitors that operate downstream of SMO, setting the stage for the clinical use of GLI antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113713 · Cited by 1,464
Self-citationActivating Smoothened mutations in sporadic basal-cell carcinoma
Xie, J., Murone, M., Luoh, S.-M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J. M., Lam, C.-W., Hynes, M., Goddard, A., et al. (1998) · Nature · doi:10.1038/34201 · Cited by 1,334
Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006
Rogers, H. W., Weinstock, M. A., Harris, A. R., Hinckley, M. R., Feldman, S. R., Fleischer, A. B., & Coldiron, B. M. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.19 · Cited by 1,185
Structure-Function of the G Protein–Coupled Receptor Superfamily
Katritch, V., Cherezov, V., & Stevens, R. C. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032112-135923 · Cited by 1,054
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
Yauch, R. L., Dijkgraaf, G. J. P., Alicke, B., Januario, T., Ahn, C. P., Holcomb, T., Pujara, K., Stinson, J., Callahan, C. A., Tang, T., et al. (2009) · Science · doi:10.1126/science.1179386 · Cited by 839
Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition
Kool, M., Jones, D. T. W., Jäger, N., Northcott, P. A., Pugh, T. J., Hovestadt, V., Piro, R. M., Esparza, L. A., Markant, S. L., Remke, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.004 · Cited by 762
Buonamici, S., Williams, J., Morrissey, M., Wang, A., Guo, R., Vattay, A., Hsiao, K., Yuan, J., Green, J., Ospina, B., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001599 · Cited by 562
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
Amakye, D., Jagani, Z., & Dorsch, M. (2013) · Nature Medicine · doi:10.1038/nm.3389 · Cited by 547
Cited by
Clonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534
Self-citationThe great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Peris, K., Fargnoli, M. C., Garbe, C., Kaufmann, R., Bastholt, L., Seguin, N. B., Bataille, V., Marmol, V. D., Dummer, R., Harwood, C. A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.003 · Cited by 599
Cameron, M. C., Lee, E., Hibler, B. P., Barker, C. A., Mori, S., Cordova, M., Nehal, K. S., & Rossi, A. M. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.060 · Cited by 525
Lebbe, C., Becker, J. C., Grob, J.-J., Malvehy, J., del Marmol, V., Pehamberger, H., Peris, K., Saiag, P., Middleton, M. R., Bastholt, L., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.131 · Cited by 500
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma
Bonilla, X., Parmentier, L., King, B., Bezrukov, F., Kaya, G., Zoete, V., Seplyarskiy, V. B., Sharpe, H. J., McKee, T., Letourneau, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3525 · Cited by 490
Structural basis of Smoothened regulation by its extracellular domains
Byrne, E. F. X., Sircar, R., Miller, P. S., Hedger, G., Luchetti, G., Nachtergaele, S., Tully, M. D., Mydock-McGrane, L., Covey, D. F., Rambo, R. P., et al. (2016) · Nature · doi:10.1038/nature18934 · Cited by 360
Update on Keratinocyte Carcinomas
Nehal, K. S., & Bichakjian, C. K. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1708701 · Cited by 315
Peris, K., Fargnoli, M. C., Kaufmann, R., Arenberger, P., Bastholt, L., Seguin, N. B., Bataille, V., Brochez, L., del Marmol, V., Dummer, R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113254 · Cited by 308
Pietrobono, S., Gagliardi, S., & Stecca, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00556 · Cited by 303
Hedgehog Signaling: From Basic Biology to Cancer Therapy
Wu, F., Zhang, Y., Sun, B., McMahon, A. P., & Wang, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.02.010 · Cited by 302
Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy
Pak, E., & Segal, R. A. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.07.026 · Cited by 301
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
Sánchez-Danés, A., Larsimont, J.-C., Liagre, M., Muñoz-Couselo, E., Lapouge, G., Brisebarre, A., Dubois, C., Suppa, M., Sukumaran, V., del Marmol, V., et al. (2018) · Nature · doi:10.1038/s41586-018-0603-3 · Cited by 139
G protein–coupled receptors control the sensitivity of cells to the morphogen Sonic Hedgehog
Pusapati, G. V., Kong, J. H., Patel, B. B., Gouti, M., Sagner, A., Sircar, R., Luchetti, G., Ingham, P. W., Briscoe, J., & Rohatgi, R. (2018) · Science Signaling · doi:10.1126/scisignal.aao5749 · Cited by 91
Pace, J. R., DeBerardinis, A. M., Sail, V., Tacheva-Grigorova, S. K., Chan, K. A., Tran, R., Raccuia, D. S., Wechsler-Reya, R. J., & Hadden, M. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01718 · Cited by 60
Medulloblastoma: Molecular understanding, treatment evolution, and new developments
Liu, X., Ding, C., Tan, W., & Zhang, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107516 · Cited by 54
Li, C.-L., Fang, Z.-X., Wu, Z., Hou, Y.-Y., Wu, H.-T., & Liu, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113616 · Cited by 46
RetractedHaensel, D., Daniel, B., Gaddam, S., Pan, C., Fabo, T., Bjelajac, J., Jussila, A. R., Gonzalez, F., Li, N. Y., Chen, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37993-w · Cited by 29
Self-citation
Metadata
- Authors
- Atwood, S. X., Sarin, K. Y., Whitson, R. J., Li, J. R., Kim, G., Rezaee, M., Ally, M. S., Kim, J., Yao, C., Chang, A. L. S., Oro, A. E., & Tang, J. Y.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 27
- Issue
- 3
- Pages
- 342-353
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2108444995
- Cited by
- 404
- References
- 28
- FWCI
- 18.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.